Zhitong Finance App News, Corning Jerry Pharmaceutical-B (09966.HK) announced that JSKN033 (a high-concentration subcutaneous compound formulation composed of human epidermal growth factor receptor 2 (“HER2”) bispecific antibody conjugate drug (“ADC (s)”) and a procedural death ligand 1 (“PD-L1”) immune checkpoint inhibitor) has obtained the China National Drug Administration (“State Drug Administration”) Drug Evaluation Center (“CDE”) has agreed to carry out a single drug containing platinum-containing chemotherapy and chemotherapy D-1/PD-L1 inhibitors A phase III clinical study of recurrent or metastatic cervical cancer that failed to be treated (Study ID: JSKN033-301).

Zhitong Finance App News, Corning Jerry Pharmaceutical-B (09966.HK) announced that JSKN033 (a high-concentration subcutaneous compound formulation composed of human epidermal growth factor receptor 2 (“HER2”) bispecific antibody conjugate drug (“ADC (s)”) and a procedural death ligand 1 (“PD-L1”) immune checkpoint inhibitor) has obtained the China National Drug Administration (“State Drug Administration”) Drug Evaluation Center (“CDE”) has agreed to carry out a single drug containing platinum-containing chemotherapy and chemotherapy D-1/PD-L1 inhibitors A phase III clinical study of recurrent or metastatic cervical cancer that failed to be treated (Study ID: JSKN033-301).